Company Founded
Orphalan established in Paris with a mission to serve rare disease patients across Europe
Our Story
Orphalan was established in 2011 with a clear focus: to develop and commercialise treatments for patients with rare diseases. What began as a dedicated effort in Wilson's disease has evolved into a comprehensive rare disease platform serving patients across multiple therapeutic areas.
Our primary focus is on rare, often serious diseases where current therapeutic options do not exist, are limited, or are associated with significant challenges for patients. Our efforts have resulted in the development and commercialisation of therapies in global markets, including Europe and the United States, with further submissions in progress to make our products available to patients worldwide.
In 2025, we acquired Orphelia, strengthening our capabilities and expanding our portfolio while maintaining our patient-focused approach and rare disease expertise.
En savoir plus